Plasma determination of iron, transferrin and ferritin
BiologicalIron, transferrin and ferritin levels in plasma
NCT Number: NCT05133999
The purpose of this study is to determine whether increased transferrin saturation in plasma (that reflects iron overload and/or low transferrin) is an independent risk factor for ROP development and severity.
Preterm infants born at <31 week's post-menstrual age (PMA) or ≤1250g of birth weight will be included. Iron parameters in plasma will be measured during the first month of life. Retinopathy of prematurity (ROP) will be screened as currently recommended. The relationship between plasma iron parameters and ROP development and/or severity will be established.
Looking for future studies?
Notify Me24 week–31 week
All sexes
Observational
Ophtalmology department _ Necker Enfants Malades Hospital, Paris, France
The incidence of ROP, the main cause of vision impairment in children, is increasing parallel to the recent changes in practices targeting higher oxygen saturation in preterm babies in many countries following the publication of five trials that showed higher rates of death with lower oxygen saturations. The main risk factor for ROP development is oxygen excess. Oxygen contributes to the formation of reactive oxygen species and to lipid peroxidation which leads to vasoconstriction, vascular cytotoxicity, and arrest of vascular development causing ischemia of retinal neurons, thereby promoting the development of ROP.
90% of extremely low birth weight infants need red blood cell transfusions (RBCT) due to their immature erythropoiesis, frequent blood sampling and small circulating blood volume. RBCT are a major source of iron overload and ferritin plasma levels may remain elevated for several weeks after transfusions. It has been shown that blood transfusion is a risk factor of ROP in preterm infants. However, whether this relationship is mediated by an increased iron load remains controversial.
Only two studies, conducted before the 2000s, identified plasma iron overload as a risk factor for ROP. These studies with a limited number of patients, showed contradictory results, failing to draw a conclusion.
Excess iron worsens oxidative stress. Iron catalyzes the Fenton reaction which leads to the formation of reactive oxygen species. In addition a transferrin deficiency (the main iron chelator) has been suggested in premature infants. The oxidative stress observed in ROP could therefore be the consequence not only of oxygen therapy but also of iron overload.
The main objective of this study is to determine whether increased transferrin saturation in plasma (that reflects iron overload and/or low transferrin) is an independent risk factor for ROP development and severity.
The secondary aims/objectives are :
Study duration will be 29 months, with an inclusion period of 24 months and a last visit for ROP evaluation at 45 week's post-menstrual age (PMA).
A total of 175 patients should be included: 35 with ROP and 140 without ROP.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Iron, transferrin and ferritin levels in plasma
ROP screening using wide field digital retinal imaging according to current recommendations.
Time frame: From 31 to 45 weeks' post menstrual age (PMA) [= (term + 4 weeks of life)].
Presence of ROP development (any stage / any zone in at least one eye) during follow-up.
Time frame: at 1 week of life
Blood dosage
Time frame: at birth, 2, 3, and 4 weeks of life
Blood dosage, in µmol/l
Time frame: at birth, 2, 3, and 4 weeks of life
Blood dosage, in g/l
Time frame: at birth, 2, 3, and 4 weeks of life
Blood dosage, in µg/l
Time frame: during follow-up about 5 months, up to 45 weeks' PMA
according to International Classification of Retinopathy of Prematury (ICROP3 classification)
Time frame: during follow-up about 5 months, up to 45 weeks' PMA
Laser, anti-VEGF injections, surgery
Time frame: during follow-up about 5 months, up to 45 weeks' PMA
Number of each intervention if a treatment was needed
Time frame: At 36 weeks' PMA
death or presence of monitoring :
Assistance Publique - Hôpitaux de Paris
Other
Iron, Transferrin and Retinopathy of Prematurity (ROP): Towards New Pathophysiological Mechanisms.
Acronym: Fer-ROP
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00895869
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Eye Diseases
Edinburgh, United Kingdom
View Trial DetailsNCT03824782
Apnea, Arrhythmias, Cardiac
Toronto, Ontario, Canada
View Trial DetailsNCT07016984
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Eye Diseases
Sariyer, İ̇stanbul, Turkey (Türkiye)
View Trial DetailsNCT05152862
Birth Weight, Body Weight
Corbeil-Essonnes, France
View Trial Details